CRISPRÎÄ¿âɸѡ
ЧÀÍÓÅÊÆ
ЧÀÍÄÚÈÝÓë½»¸¶±ê×¼
| ЧÀÍÏîÄ¿ | ЧÀÍÏêÇé | ½»¸¶±ê×¼ |
|---|---|---|
|
sgRNAÎÄ¿âÉè¼Æ¶¨ÖÆ¡¢ À©Ôö¡¢ÖÊ¿Ø |
sgRNAÉè¼Æ¡¢sgRNA-oligo poolºÏ³É¡¢ÎÄ¿âÖÊÁ£¹¹½¨¡¢ÎÄ¿âÖÊÁ£À©Ôö¡¢NGSÖÊ¿Ø |
ÎÄ¿âÖÊÁ££º100ug NGSÖʿر¨¸æ£¨ÁýÕÖ¶È£¾99%£¬£¬£¬£¬£¬£¬¾ùÒ»ÐÔ£¼10£© |
| Cas9ÎÈתϸ°ûÖê¶¨ÖÆ | Cas9Âý²¡¶¾°ü×°¡¢Cas9ÎÈתÖê¹¹½¨¡¢±à¼»îÐÔ¼ì²â | Cas9ÎÈתÖ꣨1×106/Ö꣩ |
|
ÎÄ¿âÂý²¡¶¾°ü×° |
ÎĿⲡ¶¾°ü×°ÓëµÎ¶È²â¶¨£¨Ï¸°ûµÎ¶¨·¨£©£¬£¬£¬£¬£¬£¬È·±£»£»£»£»£»£»î²¡¶¾µÎ¶È£¾1×106 TU/ml |
С¹æ¸ñ£º1×108 TU×ÜÁ¿£»£»£»£»£»£» Öйæ¸ñ£º5×108 TU×ÜÁ¿£»£»£»£»£»£» ´ó¹æ¸ñ£º1×109 TU×ÜÁ¿£»£»£»£»£»£» ²¡¶¾µÎ¶È¼ì²â±¨¸æ |
| ÎÄ¿âϸ°û¹¹½¨ | MOI£¼0.3µÄתȾÌõ¼þ̽Ë÷¡¢ÎÄ¿âϸ°ûpool¹¹½¨ |
С¹æ¸ñ£º1×107 ϸ°û×ÜÁ¿£»£»£»£»£»£» Öйæ¸ñ£º5×107 ϸ°û×ÜÁ¿£»£»£»£»£»£» ´ó¹æ¸ñ£º1×108 ϸ°û×ÜÁ¿£»£»£»£»£»£» |
| ¹¦Ð§É¸Ñ¡ÊµÑé | ¸öÐÔ»¯µÄ¹¦Ð§É¸Ñ¡Ð§ÀÍ£ºÒ©Îïɸѡ¡¢²¡¶¾Ñ¬È¾¡¢Ï¸¾úѬȾ¡¢Á÷ʽ·ÖÑ¡µÈ | ʵÑ鱨¸æ |
| NGSÆÊÎö | sgRNA²âÐò½¨¿âºÍNGS²âÐò¡¢ÉúÐÅÆÊÎö | ʵÑ鱨¸æ¡¢NGS²âÐòÔʼÊý¾Ý |
ЧÀÍÓÅÊÆ
½»¸¶ÐÎʽ¶àÑù
¶À¼Ò¿ª·¢
¸öÐÔ»¯µÄÉúÐÅÆÊÎö
һվʽЧÀÍ
ЧÀÍÁ÷³Ì
ЧÀͰ¸Àý
Advantage and Characteristic
Optimazied Strategy
Optimazied Strategy
Optimazied Strategy
Optimazied Strategy
¾«Ñ¡¿Í»§ÎÄÕÂ
Deep whole-genome analysis of 494 hepatocellular carcinomas
È«ÇòÁè¼ÝÒ»°ëµÄ¸Îϸ°û°©£¨HCC£©²¡Àý±¬·¢ÔÚÖйú£¬£¬£¬£¬£¬£¬µ«ÏÖÔÚÕë¶ÔÖйúÈËȺÖÐÒÒÐ͸ÎÑײ¡¶¾£¨HBV£©Ïà¹ØHCCµÄÈ«»ùÒò×éÆÊÎöÑо¿ºÜÊÇÓÐÏÞ¡£¡£¡£¡£ÎªÁËÍ»ÆÆÕâÖÖÏÞÖÆ£¬£¬£¬£¬£¬£¬Ñо¿Ö°Ô±Æô¶¯ÁË“Öйú¸Î°©Í¼Æ×ÏîÄ¿”£¨CLCA£©£¬£¬£¬£¬£¬£¬Ö¼ÔÚ¶ÔÖйúÈËȺÖеÄHCC¾ÙÐдó¹æÄ£µÄÈ«»ùÒò×éÆÊÎöÒÔÃ÷È·ÆäÆæÒìµÄ·¢²¡»úÖÆºÍ½ø»¯Àú³Ì¡£¡£¡£¡£¸ÃÏîÄ¿¶Ô494ÀýHCCÖ×ÁöÑù±¾¾ÙÐÐÁËÉî¶ÈÈ«»ùÒò×é²âÐò£¨Æ½¾ù²âÐòÉî¶ÈΪ120×£©£¬£¬£¬£¬£¬£¬²¢ÆÊÎöÁËÆ¥ÅäµÄ±ÈÕÕѪҺÑù±¾£¬£¬£¬£¬£¬£¬Õ¹ÏÖÁËHBVÏà¹ØHCCµÄÏêϸ»ùÒò×éÌØÕ÷¡£¡£¡£¡£Ñо¿·¢Ã÷£¬£¬£¬£¬£¬£¬³ýÁËÒÑÖªµÄ±àÂëÇøÇý¶¯»ùÒò£¨ÈçTP53ºÍCTNNB1£©Í⣬£¬£¬£¬£¬£¬»¹±£´æ6¸öеıàÂëÇøÇý¶¯»ùÒò£¨°üÀ¨FGA£©ºÍ31¸ö·Ç±àÂëÇøÇý¶¯»ùÒò¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬Ñо¿»¹Õ¹ÏÖ5ÖÖеÄÍ»±äÌØÕ÷£¨°üÀ¨SBS_H8£©£¬£¬£¬£¬£¬£¬ÒÔ¼°HBVÕûºÏÐγÉϸ°ûÍâ»·×´DNA£¨ecDNA£©µÄÕ÷Ï󣬣¬£¬£¬£¬£¬ÕâЩecDNA¿Éµ¼Ö°©»ùÒòÀ©ÔöºÍ±í´ïÔöÌí¡£¡£¡£¡£Í¨¹ý¹¦Ð§Ñé֤ʵÑ飬£¬£¬£¬£¬£¬Ñо¿Ö°Ô±Ö¤ÊµÁËFGA¡¢PPP1R12BºÍKCNJ12µÈ»ùÒòµÄÍ»±äÄܹ»ÏÔÖøÓ°ÏìHCCϸ°ûµÄÔöÖ³¡¢Ç¨áãºÍÇÖÏ®ÄÜÁ¦¡£¡£¡£¡£ÕâÏîÑо¿Ð§¹û²»µ«¸»ºñÁËÈËÃǶÔHCC»ùÒò×éѧµÄÃ÷È·£¬£¬£¬£¬£¬£¬Ò²ÎªHCCµÄÕï¶ÏºÍÖÎÁÆÌṩÁËеÄDZÔڰе㡣¡£¡£¡£

ºòÑ¡Çý¶¯Òò×Ӹſö
Targeted Macrophage CRISPR-Cas13 mRNA Editing in Immunotherapy for Tendon Injury
¼¡ëìËðÉ˼±ÐÔÑ×Ö¢ÆÚÖУ¬£¬£¬£¬£¬£¬¾ÞÊÉϸ°ûÌ«¹ý¼¤»î»áµ¼Ö±àÂë¹ÇÇÅÂѰ×OPNµÄSPP1¹ý±í´ï£¬£¬£¬£¬£¬£¬Ó°Ïì×éÖ¯ÔÙÉú¡£¡£¡£¡£CRISPR-Cas13ÓÉÓÚ¾ßÓÐRNA±à¼ºÍ¿ìËÙ½µ½âµÄÄÜÁ¦£¬£¬£¬£¬£¬£¬ÔÚ×éÖ¯ÐÞ¸´·½Ãæ¾ßÓÐÖØ´óDZÁ¦£¬£¬£¬£¬£¬£¬µ«È±·¦ºÏÊÊÓÐÓõĵÝËÍÒªÁì¡£¡£¡£¡£¶Ô´Ë£¬£¬£¬£¬£¬£¬Ñо¿Ö°Ô±ÏµÍ³É¸Ñ¡ÁËÕë¶Ô¾ÞÊÉϸ°ûµÄÑôÀë×Ó¾ÛºÏÎ£¬£¬£¬£¬£¬¿ª·¢ÁËÒ»ÖÖÄܹ»¸ßЧµÝËÍCas13ºËÌǺËÂѰ׸´ºÏÎCas13 RNP£©½øÈë¾ÞÊÉϸ°ûµÄÄÉÃ×´ØÔØÌå¡£¡£¡£¡£Í¨¹ý·´Ó¦ÐÔÑõÖÖ£¨ROS£©ÏìÓ¦ÐÔÊÍ·Å»úÖÆ£¬£¬£¬£¬£¬£¬¸ÃϵͳÄܹ»ÔÚ¼¡ëìËðÉ˵ļ±ÐÔÑ×֢΢ÇéÐÎÖÐÌØÒìÐÔÒÖÖÆ¾ÞÊÉϸ°ûÖÐSPP1µÄ¹ý±í´ï¡£¡£¡£¡£ÊµÑéЧ¹ûÅú×¢£¬£¬£¬£¬£¬£¬ÕâÖÖ°ÐÏò²ßÂÔÏÔÖøïÔÌÁËËðÉËÓÕµ¼µÄSPP1±¬·¢¾ÞÊÉϸ°ûµÄ·ºÆð£¬£¬£¬£¬£¬£¬½µµÍÁ˳ÉÏËάϸ°ûµÄ¼¤»î£¬£¬£¬£¬£¬£¬²¢¼õÇáÁ˼¡ëìÖÜΧµÄÕ³Á¬Ðγɡ£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬¸ÃÑо¿»¹Õ¹ÏÖÁËSPP1ͨ¹ýCD44/AKTÐźÅͨ·Ôö½ø³ÉÏËάϸ°û»î»¯ºÍǨáãµÄ»úÖÆ£¬£¬£¬£¬£¬£¬²¢Í¨¹ýÒÖÖÆÕâһͨ·ÓÐÓûº½âÁ˼¡ëìËðÉ˺óµÄÕ³Á¬ÎÊÌâ¡£¡£¡£¡£

ÓÃÓÚPAÖÎÁƵľÞÊÉϸ°ûÃâÒß΢ÇéÐ줻îmRNA±à¼²ßÂÔµÄʾÒâͼ
Electrical stimulation of piezoelectric BaTiO3 coated Ti6Al4V scaffolds promotes anti-inflammatory polarization of macrophage and bone repair via MAPK/JNK inhibition and OXPHOS activation
¼¹ËèËðÉË£¨SCI£©ÊÇÒ»ÖÖµ¼Ö¸ÐÊÜ×ÔÖ÷Éñ¾ºÍÔ˶¯¹¦Ð§µÄÓÀÊÀÐÔË𺦵ÄÑÏÖØÖ²ÐÐÔ¼²²¡¡£¡£¡£¡£¸Éϸ°ûÁÆ·¨£¬£¬£¬£¬£¬£¬ÓÈÆäÊǼä³äÖʸÉϸ°û£¨MSCs£©£¬£¬£¬£¬£¬£¬ÔÚSCIÖÎÁÆÖÐÕ¹ÏÖ³öÖØ´óDZÁ¦µ«ÆäÔÙÉúÄÜÁ¦ÓÐÏÞ£¬£¬£¬£¬£¬£¬ÕâÏÞÖÆÁËÆäÔÚ×éÖ¯ÔÙÉúÖеÄÓ¦Óᣡ£¡£¡£Ñо¿ÍŶÓÊӲ쵽ABPCsÑÜÉúµÄEVs£¨EVsABPC£©¿ÉÄÜЯ´øÔö½ø×éÖ¯ÔÙÉúµÄÉúÎï»îÐÔÐźţ¬£¬£¬£¬£¬£¬Òò´ËËûÃÇ´Ó¹½ÇÑ¿»ù×æÏ¸°û£¨ABPCs£©ÖÐÌáÈ¡²¢ÐÞÊÎÁËϸ°ûÍâÄÒÅÝ£¨EVsABPC£©£¬£¬£¬£¬£¬£¬²¢½«ÆäÓ¦ÓÃÓÚ¼¹ËèËðÉË£¨SCI£©µÄÖÎÁÆÑо¿¡£¡£¡£¡£Ñо¿Ö°Ô±·¢Ã÷EVsABPCÄܹ»ÏÔÖøÔöÇ¿Éñ¾¸Éϸ°û£¨NSCs£©µÄÔöÖ³£¬£¬£¬£¬£¬£¬Ôö½øÖáÍ»Éú³¤£¬£¬£¬£¬£¬£¬ïÔÌÉñ¾ÔªµòÍö£¬£¬£¬£¬£¬£¬²¢Í¨¹ýµ÷ÀíÑ×Ö¢·´Ó¦½«¾ÞÊÉϸ°û´Ó´ÙÑ×µÄM1Ðͼ«»¯Îª¿¹Ñ×µÄM2ÐÍ¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬¾Óɹ¤³Ì»¯Ë¢ÐµÄEVsABPC£¨Í¨¹ý¼¤»îϸ°û´©Í¸ëÄÐÞÊΣ©Äܹ»¸üÓÐÓõذÐÏòSCIËðÉ˲¿Î»£¬£¬£¬£¬£¬£¬ÏÔÖø¸ÄÉÆÉñ¾ÔÙÉúºÍÔ˶¯¹¦Ð§»Ö¸´¡£¡£¡£¡£ÕâЩЧ¹ûÅú×¢£¬£¬£¬£¬£¬£¬EVsABPCÊÇÒ»ÖÖ¼«¾ßDZÁ¦µÄSCIÖÎÁƺòÑ¡¼Æ»®¡£¡£¡£¡£

ͼ½âÕªÒª
Generation of recombinant antibodies by mammalian expression system for detecting S-metolachlor in environmental waters
S-Òì±û¼×²Ý°·£¨S-MET£©ÊÇÎÒ¹úÉú²úºÍʹÓÃÁ¿×î´óµÄ³ý²Ý¼ÁÖ®Ò»£¬£¬£¬£¬£¬£¬Æä»¯Ñ§ÌØÕ÷µ¼ÖÂÆä¿ÉÔÚÍÁÈÀÖг¤ÆÚ±£´æÒÔ¼°ÈÝÒ×ͨ¹ýÁÜÈܺͳÁ½µÎÛȾµØ±íË®ºÍµØÏÂË®£¬£¬£¬£¬£¬£¬×îÖÕÓ°ÏìÖ²ÎïÉú³¤ºÍͨ¹ýʳÎïÁ´Î£º¦ÈËÀàÉúÃü¿µ½¡¡£¡£¡£¡£¼øÓÚÏÖÓмì²âÒªÁìµÄ¾ÖÏÞÐԺͶԸßЧÆÊÎö¼¼ÊõµÄÆÈÇÐÐèÇ󣬣¬£¬£¬£¬£¬¸ÃÑо¿ÒÔS-metolachlorΪ¹¤¾ß£¬£¬£¬£¬£¬£¬Ê¹Óò¸È鶯Îï±í´ïϵͳÌìÉúÏà¹ØÖØ×鿹Ìå¡£¡£¡£¡£ÔÚÀֳɱí´ï¿¹ÌåµÄ»ù´¡ÉÏ£¬£¬£¬£¬£¬£¬Àֳɽ¨ÉèÁË»ùÓÚÕâЩ¿¹ÌåµÄÃâÒ߯ÊÎöÒªÁ죬£¬£¬£¬£¬£¬ÓÃÓÚ¼à²âÇéÐÎË®ÑùÖеÄS-Òì±û¼×²Ý°·²ÐÁô¡£¡£¡£¡£icELISAЧ¹ûÏÔʾ£¬£¬£¬£¬£¬£¬ÖØ×鿹ÌåµÄѸËٶȺÍÌØÒìÐÔÓëÇ×±¾µ¥¿¹ÏàËÆ£¬£¬£¬£¬£¬£¬¿É¼á³ÖÔÓеÄÉúÎïѧ»îÐÔ£¬£¬£¬£¬£¬£¬¹ØÓڽˮ¡¢Å©ÌïË®ºÍ×ÔÀ´Ë®ÖеÄS-MET£¬£¬£¬£¬£¬£¬¾ßÓÐÓÅÒìµÄ׼ȷÐÔºÍÖØ¸´ÐÔ¡£¡£¡£¡£

ͼ½âÕªÒª
Dumbbell probe initiated multi-rolling circle amplification assisted CRISPR/Cas12a for highly sensitive detection of clinical microRNA
ϸСRNA£¨miRNA£©ÊÇÒ»ÀàСµÄ·Ç±àÂëRNA·Ö×Ó£¬£¬£¬£¬£¬£¬Í¨¹ýÓëÌØ¶¨°Ð»ùÒòµÄÐÅʹRNA£¨mRNA£©Ï໥×÷ÓÃÀ´µ÷¿Ø»ùÒò±í´ï¡£¡£¡£¡£miRNAÔÚ¶àÖÖ¼²²¡µÄ±¬·¢¡¢Éú³¤Àú³ÌÖÐÊÎÑÝ×ÅÖ÷Òª½ÇÉ«£¬£¬£¬£¬£¬£¬±»ÒÔΪÊǼ«¾ßDZÁ¦µÄ¼²²¡ÉúÎï±ê¼ÇÎï¡£¡£¡£¡£¸ÃÑо¿Ê¹ÓÃCRISPR/Cas12a¿ª·¢ÁËÒ»ÖÖΪDBmRCAµÄÐÂÐÍmiRNA¼ì²â¼¼Êõ¡£¡£¡£¡£¸Ã¼¼ÊõʹÓÃÎÞÅþÁ¬Ã¸µÄÑÆÁå̽ÕëºÍ¸ßѸËٶȵÄCRISPR/Cas12aÐźÅÊä³ö²ßÂÔ£¬£¬£¬£¬£¬£¬ÊµÏÖÁËÔÚ30·ÖÖÓÄÚ¶ÔmiRNAµÄ¸ß¾«¶È¶¨Á¿ÆÊÎö¡£¡£¡£¡£Ñо¿ÍŶÓͨ¹ýÁÙ´²Ñù±¾ÑéÖ¤Á˸ü¼ÊõµÄÓÐÓÃÐÔ£¬£¬£¬£¬£¬£¬·¢Ã÷miR-200aºÍmiR-126Ôڷΰ©×éÖ¯Öеıí´ïˮƽÏÔÖø½µµÍ£¬£¬£¬£¬£¬£¬ÇҸü¼ÊõÓë¹Å°åÒªÁìЧ¹ûÒ»Ö¡£¡£¡£¡£DBmRCA¼¼Êõ¾ßÓÐʱ¼äЧÂʸߡ¢Ñ¸ËÙ¶ÈÇ¿ºÍ²Ù×÷Á÷³Ì¼ò»¯µÈÓŵ㣬£¬£¬£¬£¬£¬ÎªÁÙ´²miRNAÆÊÎöÌṩÁËÒ»ÖÖ¿É¿¿µÄ¹¤¾ß£¬£¬£¬£¬£¬£¬ÓÐÍûÖúÁ¦·Î°©µÄÔçÆÚÕï¶ÏºÍÖÎÁÆ¡£¡£¡£¡£

ͼ½âÕªÒª
FAQ
ÔõÑùÑ¡ÔñÈ«»ùÒò×é»òÑÇ»ùÒò×éCRISPRÎĿ⣿£¿£¿
µ¥ÖÊÁ£ÏµÍ³ºÍË«ÖÊÁ£ÏµÍ³ÎÄ¿âÔØÌåµÄÇø±ð£¿£¿£¿
1£©Ìá¸ß±à¼Ð§ÂÊ£ºCas9ÂѰ׺ÍsgRNAÔÚ²î±ðµÄÔØÌåÉÏ×ÔÁ¦¡¢Îȹ̱í´ï£¬£¬£¬£¬£¬£¬¿ÉÒÔÌá¸ß±à¼Ð§ÂÊ¡£¡£¡£¡£
2£©ÎÞаÐÔ£º¿ÉÒÔÆ¾Ö¤ÊµÑéÐèÒª£¬£¬£¬£¬£¬£¬ÎÞаµØ¾ÙÐÐÔØÌåÉè¼ÆºÍ¹¹½¨¡£¡£¡£¡£ºÃ±ÈÒ»¸öÔØÌå×°ÔØÁ½¸ösgRNA±í´ïºÐ¡£¡£¡£¡£
ÔõÑùÑ¡ÔñºÏÊʵÄϸ°û¾ÙÐÐÎÄ¿âɸѡ£¡£¡£¡£¿£¿£¿
1£©ÓëÑо¿Ä¿µÄÏà·û
2£©sgRNAÎÄ¿â°ÐÏòµÄ»ùÒòÒªÓëϸ°ûµÄÊôÔ´Ïà·û
3£©Ï¸°û¿ÉÒÔÎȹ̴«´ú
4£©×ªÈ¾Ð§Âʸß
Ö»¹Ü²»Ñ¡ÓÃÔ´úϸ°û¡£¡£¡£¡£ÓÉÓÚÔ´úϸ°ûÎÞ·¨Îȹ̴«´ú£¬£¬£¬£¬£¬£¬¿ÉÄÜÔÚÎÄ¿âɸѡʵÑéµÄÀú³ÌÖУ¬£¬£¬£¬£¬£¬Ô´úϸ°ûÒѾ·ºÆð´ó×ÚéæÃü£¬£¬£¬£¬£¬£¬ÎÞ·¨Íê³ÉʵÑé¡£¡£¡£¡£ÈôÊÇÑ¡ÓÃÔ´úϸ°û¾ÙÐÐÎÄ¿âɸѡ£¬£¬£¬£¬£¬£¬ÎªÏàʶ¾öÉÏÊöµÄΣº¦£¬£¬£¬£¬£¬£¬¿ÉÒÔͨ¹ý½µµÍϸ°ûÁýÕֶȺÍÑ¡ÔñgRNAÊý½ÏСµÄÎÄ¿â¾ÙÐÐɸѡ£¬£¬£¬£¬£¬£¬¾¡¿ÉÄܽµµÍÎÄ¿âϸ°û³ØµÄÊýÄ¿ºÍËõ¶ÌʵÑéÖÜÆÚ¡£¡£¡£¡£
ÍêÃÀÕæÈË